Gd-DTPA增强的MRI在脑转移瘤诊断中的应用

目的探讨Gd-DTPA增强MRI对脑转移瘤的诊断价值及意义。方法回顾分析100例脑部转移瘤病人的平扫和增强MRI资料。结果100例脑转移瘤病人,平扫检出198个转移病灶,增强扫描检出354个转移病灶。平扫检出坏死囊变病灶85个,增强扫描检出183个。平扫检出病灶最小直径0.8cm,增强扫描检出病灶最小直径0.3cm,98例增强后可清晰显示病灶边界。16例没有症状的病人平扫7例未显示病灶,增强后均发现有转移病灶。结论Gd-DTPA是一种安全的MRI对比剂,增强MRI在显示脑转移瘤的大小、数目、边界、内部结构及位置等方面具有明显优势,可以帮助早期诊断。     

流动敏感黑血序列三维T1WI增强扫描在脑转移瘤中的应用价值

【摘要】目的：探讨3.0T磁共振流动敏感黑血序列三维T1加权增强扫描（FSBB 3D CE-T1WI）在脑转移瘤中的应用价值。方法：回顾性将2021年1月－2022年8月在本院就诊且经临床和影像检查证实的52例脑转移患者纳入研究。所有患者分别行颅脑FSBB 3D CE-T1WI、FSE CE-T1WI和快速梯度回波序列三维T1加权对比增强（FFE 3D CE-T1WI）扫描，采用卡方检验或Fisher精确概率检验比较3个序列之间病灶检出率的差异。结果：经随访证实颅内转移灶总数为371个，FSBB 3D CE-T1WI的检出率99.73%（370/371）， FFE 3D CE-T1WI的检出率为83.02%（308/371），FSE CE-T1WI的检出率为78.44%（291/371），三者之间检出率的差异有统计学意义（χ2=82.748，P＜0.05）。分层分析：直径＜3mm的转移灶共160个，FSE CE-T1WI、FFE 3D CE-T1WI和FSBB 3D CE-T1WI的检出率分别为50.62%、60.62%和99.37%，三个序列之间检出率的差异有统计学意义（χ2=101.436,P＜0.05）；对于直径3~10mm的转移灶，FSE CE-T1WI、FFE 3D CE-T1WI和FSBB 3D CE-T1WI的检出率分别为99.38%、100%和100%，三个序列之间检出率的差异无统计学意义（P>0.05）；对直径>10mm的转移灶，三个序列的检出率均为100%，差异无统计学意义（P>0.05）。结论：FSBB 3D CE-T1WI在检出脑转移瘤方面要优于常规和高分辨序列MR增强扫描，值得临床推广。     

低场MR增强扫描对脑转移瘤的诊断价值

目的：探讨低场MR增强扫描对脑转移瘤的诊断价值.方法：回顾分析70例脑部转移瘤病人用0.5T超导型磁共振扫描仪做的平扫和Gd-DTF＇A增强扫描的MRI征象.结果：70例脑转移瘤病人,平扫检出118个转移灶,Gd-DTP＇A增强扫描检出239个转移灶.平扫检出最小病灶直径0.9 cm,增强扫描栓出最小病灶直径0.2 cm.结论：低场磁共振Gd-DTPA增强扫描既能发现平扫难以发现的脑转移瘤,又可以准确发现微小和特殊部位的转移灶,同时又可以明确病灶形态、边缘以及内部情况.为临床治疗方案的确定提供可靠依据.     

脑内结核瘤Gd-DTPA增强MRI表现特点

目的总结和分析脑内结核瘤在Gd-DTPA增强MRI上的表现特点. 资料与方法对24例脑内结核瘤患者进行平扫和Gd-DTPA增强扫描,比较和分析平扫及增强扫描MRI上的表现特点,包括病灶检出数目、分布情况、病灶的形态、信号特点等.结果结核瘤在Gd-DTPA增强扫描自旋回波T1WI上强化明显,呈结节样或环形强化,有多个病灶聚合成团的特点;病变与周边组织分界清楚.结论脑内结核瘤在增强MRI上有一定的特征性表现,Gd-DTPA增强MR检查较平扫更敏感,能早期发现脑内结核瘤.     

低场MR增强扫描及FLAIR序列对脑转移瘤诊断的评价

目的 :探讨低场MR增强扫描与FLAIR序列在脑转移瘤诊断中的价值。方法 :搜集 2 9例脑转移瘤患者 ,使用 0 .2 3TMR扫描仪 ,对比分析常规T1 WI、T2 WI、增强扫描及FLAIR序列在检出转移瘤和明确转移瘤边界方面的敏感性。结果 :增强扫描对转移瘤检出以及明确转移瘤边界的敏感性高于FLAIR、T2 WI及T1 WI ,经统计分析其差异有极显著性意义 (P <0 .0 1)。对于直径 <1.0cm的软脑膜转移瘤及皮质近蛛网膜下腔处转移瘤的检出及明确肿瘤边界的敏感性FLAIR高于常规T2 WI ,差异有显著性意义 (P <0 .0 5 ) ;对于直径≥ 1.0cm的软脑膜转移瘤、皮质近蛛网膜下腔处转移瘤及深部脑转移瘤 ,FLAIR与常规T2 WI检查差异无显著性意义 (P >0 .0 5 )。结论 :脑转移瘤的低场MRI诊断 ,增强扫描是最有价值的检查方式 ,而FLAIR可取代常规T2 WI。     

低场强MRI强化扫描对脑转移瘤的诊断价值（附49例分析）

目的：研究分析低场强MRI对脑转移瘤的诊断价值。方法：用西门子open 0.2T扫描仪，在常规扫描后再静脉快速推注Gd-DTPA 0.2-0.4ml/kg，选用T1WI条件取相应的断面。结果：49例中单发脑转移瘤11例，多发脑转移瘤38例，共检出瘤体灶133个，强化扫描比平扫多发现49个，病灶发生在幕上的121个，幕下的12个。在133个病灶中，呈弥散快速强化的87个，呈环状结节强化的有46个，均为明显强化性肿瘤。结论：低场强MRI强化扫描对脑转移瘤的病理特点的反应是敏感的。     

增强FLAIR T2WI诊断脑膜转移瘤的价值

目的:探讨脑膜转移瘤的MRI表现及增强后FLAIR序列T2WI的诊断价值。方法:回顾性分析20例脑膜转移瘤患者的病例资料,其中硬脑膜转移瘤5例,软脑膜转移瘤15例。所有病例行常规MRI平扫及SE T1WI和FLAIR序列T2WI增强扫描并进行对比分析。结果:MRI平扫检出6例,病灶边界均显示不清;MRI增强扫描检出所有病例,SE-T1WI上病变主要表现为脑膜的线状和/或结节状强化,FLAIR T2WI对软脑膜转移瘤病灶范围的显示更清楚,可鉴别强化的血管与病变。结论:MRI增强扫描是诊断脑膜转移瘤的重要检查方法,增强后FLAIR序列T2WI与SE T1WI同时使用,可提高对软脑膜转移瘤的检出率及诊断准确性。     

3T MR扩散加权成像对肝脏转移瘤的诊断价值初探

目的:探讨MR扩散加权成像(DWI)对肝脏转移瘤的诊断价值.方法:对临床确诊的25例肝脏转移瘤患者进行DWI、T2WI及Gd-DTPA-T1WI扫描,观察肝脏转移瘤的信号特征,并统计分析3种序列所检出的转移瘤数目.结果:对于直径大于1.0 cm的32个转移瘤灶,3种序列都准确检出;而直径小于1.0 cm的微小转移瘤,在T2WI上共检出76个,病灶信号均为略高信号;在DWI上共栓出85个,呈高信号;在增强门脉期T1WI上共检出68个,大部分瘤灶呈环状强化或不均匀强化.3种序列对转移瘤的检出差别无显著性意义.结论:DWI对肝脏微小转移瘤的敏感性较高,将DW与T2W、GD-DTPA-T1W 3种序列相结合,可以互相弥补各序列不足之处,将大大提高肝脏微小转移瘤灶的检出率.     

三倍量国产钆喷替酸葡甲胺增强MRI探查脑转移瘤的研究

目的 评价３倍量（０．３ｍｍｏｌ／ｇ）国产钆喷替酸葡甲胺（Ｇｄ－ＤＴＰＡ）增强ＭＲＩ探查脑转移瘤的效果。方法 用国产Ｇｄ－ＤＴＰＡ３倍量增加ＭＲＩ检查５５例怀疑脑转移瘤的患者。对ＭＲ扫描所见进行定性,定量分析。结果 ３倍量增强比常规量增强扫描发现了理多的转移病灶,分别为３７及１７５个。对３倍量增强扫描多发现的１３８个病灶的定量分析表明,３倍量增强使病灶的相对信号强度明显增高。尤其值得指出的是,２     

颅内柔脑膜转移瘤：低场MRI FLAIR序列与T1WI增强扫描对比分析

目的:评估低场MR液体衰减反转恢复(FLAIR)序列诊断颅内柔脑膜转移瘤的价值.材料和方法:回顾性分析30例颅内柔脑膜转移瘤的FLAIR序列平扫与T1WI常规剂量增强扫描的表现.结果:T1WI增强扫描检出柔脑膜转移瘤128个,而FLAIR检出117个,T1WI增强扫描检出病灶较FLAIR序列敏感(P<0.05);T1WI增强扫描明确所有病灶边界,而FLAIR序列对所有病灶的边界显示不清.结论:对于颅内柔脑膜转移瘤的低场MR诊断,T1WI增强扫描优于FLAIR序列.     

The effect of contrast dose,imaging time,and lesion size in the MR detection of intracerebral metastasis.

PURPOSETo evaluate the effect of MR contrast dose versus delayed imaging time on the detection of metastatic brain lesions based on lesion size.METHODSContrast MR examinations with gadoteridol were obtained in 45 patients with brain metastases. The patients were divided into two groups: 16 received cumulative standard dose (0.1 mmol/kg) and 29 received cumulative triple dose (0.3 mmol/kg). Both groups were evaluated at two dose levels (lower dose and higher dose) with two separate injections. Each patient received an initial bolus injection of either 0.05 (cumulative standard dose) or 0.1 (cumulative triple dose) mmol/kg of gadoteridol to reach the lower-dose level and underwent imaging immediately and 10 and 20 minutes later. Thirty minutes after injection, an additional bolus injection of 0.05 (cumulative standard dose) or 0.2 (cumulative triple dose) mmol/kg was administered to reach the cumulative higher-dose level (cumulative standard dose, 0.1 mmol/kg; cumulative triple dose, 0.3 mmol). Images were acquired immediately.RESULTSThere was no difference in the detection rate for lesions larger than 10 mm among T2-weighted, lower-dose immediate and delayed, or immediate higher-dose images in both study groups. Lesions smaller than 10 mm had improved detection with delayed imaging in both study groups; however, the immediate higher-dose studies still had the highest detection rate.CONCLUSIONIn the evaluation of small central nervous system metastases, either delayed imaging after the injection of standard contrast dose or higher contrast dose may improve their detection, and therefore affect clinical management. Higher contrast dose (cumulative triple dose) studies appear to be more effective than delayed imaging with standard dose.     

Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors

RATIONALE AND OBJECTIVES: To compare gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for magnetic resonance imaging of the liver. METHODS: The contrast agent Gd-BOPTA or Gd-DTPA was administered at a dose of 0.1 mmol/kg to 257 patients suspected of having malignant liver tumors. Dynamic phase images, spin-echo images obtained within 10 minutes of injection, and delayed images obtained 40 to 120 minutes after injection were acquired. All postcontrast images were compared with unenhanced T1-weighted and T2-weighted images obtained immediately before injection. A full safety assessment was performed. RESULTS: The contrast efficacy for dynamic phase imaging was moderately or markedly improved in 90.9% (110/121) and 87.9% (109/124) of patients for Gd-BOPTA and Gd-DTPA, respectively. At 40 to 120 minutes after injection, the cor- responding improvements were 21.7% (26/120) and 11.6% (14/121) for spin-echo sequences and 44.5% (53/119) and 19.0% (23/121) for breath-hold gradient-echo sequences, respectively. The differences at 40 to 120 minutes after injection were statistically significant (P < 0.02). Increased information at 40 to 120 minutes after injection compared with information acquired within 10 minutes of injection was available for 24.0% (29/121) of patients with Gd-BOPTA and for 14.5% (18/124) of patients with Gd-DTPA (P < 0.03). Adverse events were seen in 4.7% (6/128) and 1.6% (2/127) of patients receiving Gd-BOPTA and Gd-DTPA, respectively. The difference was not statistically significant. CONCLUSIONS: The efficacy of Gd-BOPTA is equivalent to that of Gd-DTPA for liver imaging during the dynamic phase and superior during the delayed (40-120 minutes) phase of contrast enhancement. Both agents are safe for use in magnetic resonance imaging of the liver.     

Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions.

PURPOSETo compare the efficacy of single-dose gadolinium with magnetization transfer contrast (MTC) with that of triple-dose gadolinium in detecting enhancing multiple sclerosis lesions.METHODSTwenty-one patients with multiple sclerosis were examined with MR imaging first with 0.1 mmol/kg gadolinium (single dose) and then, after 24 to 72 hours, with 0.3 mmol/kg gadolinium (triple dose). T2-weighted fast spin-echo and T1-weighted spin-echo MR images with and without MTC were obtained before contrast administration followed by either T1-weighted spin-echo images with MTC (single dose) or conventional T1-weighted spin-echo images (triple dose), starting 5, 17, and 29 minutes after contrast administration. All images were evaluated in a blinded fashion and scored in random order by two readers. Outcome parameters included number of enhancing lesions, number of active MR examinations (those containing at least one enhancing lesion), contrast ratio (signal intensity of enhancing lesion divided by signal intensity of normal-appearing white matter), and size of enhancing lesions.RESULTSEighty-one percent more enhancing lesions and 49% more active MR examinations were detected when a triple dose of gadolinium was used as compared with a single dose. The level of agreement between readers as to the number of enhancing lesions was significantly higher for triple-dose than for single-dose gadolinium. With triple-dose gadolinium, contrast ratios and areas of enhancement increased by 10% and 33%, respectively. Delayed imaging increased the size of the lesion by 11% on single-dose MTC images and by 18% on triple-dose images.CONCLUSIONTriple-dose gadolinium is more effective (higher sensitivity and interobserver agreement) than single-dose gadolinium in combination with MTC in detecting enhancing multiple sclerosis lesions.     

Gadoteridol in multiple sclerosis patients: A comparison of single and triple dose with immediate vs. delayed imaging

Enhancement of lesions in multiple sclerosis (MS) has been investigated using standard and high doses of gadolinium. The purposes of this study are to compare the relative merits of single and triple dose as well as examine the merits of delayed triple-dose images in a large group of patients. Thirty-seven patients with multiple sclerosis underwent contrast enhanced brain magnetic resonance imaging (MRI). After noncontrast images, a single dose (0.1 mmol/kg) of gadoteridol was administered. Subsequently, axial T1-weighted images were obtained immediately after administration, and again after a delay of approximately 20 minutes. After an additional 0.2-mmol/kg dose was administered, to provide a total cumulative dose of 0.3 mmol/kg of gadoteridol, immediate and delayed axial T1-weighted image sequences were repeated. The contrast-noise ratio (C/N) was calculated for each identified, enhancing lesion in each series. Furthermore, blinded readings were performed to determine the lesion detection rate. Of the forty definite lesions that underwent all four sequences, triple-dose delayed images exhibited the highest contrast-noise ratio in a significantly larger number of lesions (p < 0.0001). Triple-dose immediate and delayed scans resulted in significantly higher contrast-noise ratios (6.47 and 9.99, respectively) when compared with those of the single dose scans (3.4 for immediate scans and 5.24 for delayed) (p < 0.01). The lesion detection rate was highest for triple dose delayed (95%), followed by triple-dose immediate (83%), single-dose delayed (68%) and finally, single-dose immediate scans (43%). Triple-dose immediate was noted to have a significantly increased (p < 0.0002) lesion detection rate with respect to the standard-dose immediate scans and standard-dose delayed scans (p < 0.02). In four lesions (10% of the total number of lesions), detection occurred only with the triple-dose delayed image sequence. Triple-dose 0.3 mmol/kg gadolinium with delayed imaging resulted in the highest lesion conspicuity and the highest lesion identification rate. There was a trend of progressively increasing detection rates from single-dose immediate scans to triple-dose delayed scans. Triple-dose delayed scans resulted in significantly higher (p < 2 × 10⁻⁸) contrast noise ratios than all other sequences of this study.     

Conventional and rapid MR imaging of the liver with Gd-DTPA

Twenty-three patients with malignant hepatic tumors underwent magnetic resonance (MR) imaging before and after intravenous administration of gadolinium-diethylene-triaminepentaacetic acid (DTPA). Two different doses were used, 0.1 mmol/kg and 0.2 mmol/kg. The larger dose proved to be more effective than the smaller dose. The signal-enhancement-to-noise ratio was significantly larger in the tumor than in the liver (2 alpha less than or equal to .05). In a moderately T1-weighted spin echo (SE) sequence (SE 400/30) (repetition time [TR] msec/echo time [TE] msec), the tumor was better defined 6 minutes after administration of Gd-DTPA. More strongly T1-weighted sequences--that is, SE 200/20 and inversion recovery 1,500/35/400 (TR msec/TE msec/inversion time, msec)--showed significantly worse contrast between tumor and liver (signal-difference-to-noise ratio [SD/N]) 10 and 15 minutes after administration (2 alpha less than or equal to .05). On the other hand, the low SD/N in the rapid MR imaging sequence was significantly improved (2 alpha less than or equal to .05). The most important indications for administration of Gd-DTPA in diagnosing hepatic tumors are the presentation of perfusion conditions and contrast optimization in rapid MR images.     

Increased detection of intracranial metastases with intravenous Gd-DTPA

Three patients with intracranial metastases were studied with magnetic resonance imaging at 1.5 T before and after intravenous administration of 0.1 mmol/kg gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA). Axial pre- and postcontrast images demonstrated a total of six and 38 metastases, respectively. Of the 35 lesions detected only after administration of contrast material, all were less than 10 mm, and none had evidence of surrounding edema. Lesion conspicuity was comparable on postcontrast mixed (T1, proton density, and T2) images and T1-weighted images, indicating the feasibility of effectively screening for metastases with a single postcontrast spin-echo sequence providing mixed and T2-weighted images. Sagittal and coronal images depicted temporal lobe lesions not seen on axial images. No discomfort, side effects, or complications resulted from the contrast medium. The detection of additional lesions with Gd-DTPA increased the radiologic suspicion of metastatic disease, revealed locations more favorable for biopsy, prompted the search for a primary tumor, and modified therapeutic objectives and methods.     

MR imaging of the liver with Gd-BOPTA: quantitative analysis of T1-weighted images at two different doses.

This study evaluates the efficacy of gadobentate-dimeglumine (Gd-BOPTA) for enhancement of liver signal-to-noise ratio (SNR) and lesion-liver contrast-to-noise ratio (CNR) on T1-weighted spin-echo (SE) and gradient-recalled-echo (GRE) images at two different doses. Fifty patients with known or suspected liver lesions were examined at 1.5 T. T1-weighted SE (TR/TE 300/12 msec) and GRE images (TR/TE80/4.2 msec/flip angle 80 degrees) were obtained before and at 40-80 minutes and 90-120 minutes after administration of 0.05 or 0.1 mmol/kg Gd-BOPTA. Quantitative measurements of tissue signal intensity were performed at each dose. Liver showed significant enhancement after Gd-BOPTA on T1-weighted SE and GRE images (0.05 mmol: P < 0.05; 0.1 mmol: P < 0.001). The dose of 0.1 mmol/kg provided higher liver SNR than 0.05 mmol/kg. Mean liver SNR was higher on GRE than SE images (P < 0.0001). Lesion-liver CNR significantly increased on GRE images after 0.1 mmol (P < 0.05). There was a trend toward superiority of 0.1 mmol over 0.05 mmol/kg. GRE images were superior to SE images for pre- and post Gd-BOPTA lesion-liver CNR (P < 0.05). Our study suggests that Gd-BOPTA provides prolonged enhancement of liver SNR and CNR, that a dose of 0.1 mmol/Kg appears to be superior than 0.05 mmol/Kg, and that GRE techniques should be used in preference over SE techniques.     

三倍量(0.3mmol/kg)国产Gd-DTPA增强MR探查脑膜转移瘤的研究

目的 评价三倍量（０．３ｍｍｏｌ／ｋｇ）国产Ｇｄ－ＤＴＰＡ增强ＭＲ探查脑膜转移瘤的效果。材料与方法 用国产Ｇｄ－ＤＴＰＡ三倍量增强ＭＲ检查１１０例临床怀疑脑转移瘤患者。先行平扫,然后静脉注射常规量（０．１ｍｍｏｌ／ｋｇ）国产Ｇｄ－ＤＴＰＡ。注射后即刻行Ｔ１ＷＩ扫描,２０分钟后行延迟扫描。距第１次注射３０分钟后,再注射０．２ｍｍｏｌ／ｋｇ的Ｇｄ－ＤＴＰＡ,从而达到累积剂量０．３ｍｍｏｌ／ｋｇ。第２次     

Low-dose gadobenate dimeglumine versus standard-dose gadopentate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging

RATIONALE AND OBJECTIVES: The purpose of our study was to compare gadopentate dimeglumine (Gd-DTPA) and gadobenate dimeglumine (Gd-BOPTA) for the evaluation of myocardial infarction (MI) and in the grading transmural extent on late-contrast enhanced cardiac magnetic resonance imaging. MATERIALS AND METHODS: Twenty-three patients with clinically proven MI were examined with the use of 0.2 mmol/kg Gd-DTPA and 0.1 mmol/kg Gd-BOPTA in 2 days interval. All patients were examined with the use of segmented two-dimensional inversion-recovery turbo fast-field echo pulse sequence with an inversion time 210-300 milliseconds. Fifteen minutes time delay was used on both examinations after the injection of contrast agent. Contrast-to-noise ratio between normal myocardium and infarcted myocardium and signal intensity ratio (SIR) of the enhanced myocardium to blood pool was derived and compared for each contrast agent. RESULTS: A total of 61 infarcted segments were analyzed. All of the infarcted segments were visualized on both Gd-BOPTA and Gd-DTPA enhanced images. There was statistically no significant difference between 0.2 mmol/kg Gd-DTPA and 0.1 mmol/kg Gd-BOPTA in the mean contrast-to-noise ratio (10.19 versus 10.22; P = .96), SNR (14.29 versus 14.25; P = .96), and SIR (4.34 versus 4.21; P = .38) of the infarcted segments. Intraobserver agreement (kappa) between Gd-DTPA and Gd-BOPTA were R1 = 91% and R2 = 86%. Interobserver agreements between the readers were Gd-DTPA = 85% and Gd-BOPTA = 88%. CONCLUSION: According to our data, the diagnostic efficacy of 0.1 mmol/kg dose Gd-BOPTA is equivalent to that of 0.2 mmol/kg Gd-DTPA for the assessment of MI on delayed enhanced magnetic resonance images.     

Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.

PURPOSETo assess the efficacy and safety profile of high-dose (0.3 mmol/kg cumulative dose) gadoteridol in patients with suspected central nervous system metastatic disease.METHODSWe studied 67 patients using an incremental-dose technique. Patient monitoring included a medical history, physical examination, vital signs, and extensive laboratory tests within 24 hours before and after the MR examination. Precontrast T1- and T2-weighted spin-echo studies were performed, followed by intravenous injection of 0.1 mmol/kg of gadoteridol. T1-weighted images were acquired immediately after and at 10 and 20 minutes after injection. At 30 minutes an additional 0.2 mmol/kg of gadoteridol was administered (0.3-mmol/kg cumulative dose), and T1-weighted images were acquired. Cases demonstrating abnormal MR findings were assessed for efficacy by unblinded and blinded reviewers and were analyzed quantitatively.RESULTSThree adverse effects in two patients were considered to be related to gadoteridol administration. No adverse effects were serious; all self-resolved. Forty-nine cases showed abnormal MR findings and were included in the efficacy analysis. A significantly greater number of lesions was seen on the high-dose as opposed to the standard-dose images. Blinded and unblinded readers identified 5 and 8 patients, respectively, with solitary lesions on standard-dose examination and multiple lesions on high-dose examination. Two patients who had normal standard-dose findings had lesions identified on high-dose studies. Quantitative analysis of 133 lesions in 45 patients demonstrated significant increases in lesion signal intensity on high-dose studies when compared with standard-dose studies.CONCLUSIONGadoteridol can be safely administered up to a cumulative dose of 0.3 mmol/kg. High-dose contrast studies provide improved lesion detectability and additional diagnostic information over studies performed in the same patients with a 0.1-mmol/kg dose and aid in patient diagnosis and treatment. High-dose gadoteridol study may facilitate the care of patients with suspected central nervous system metastasis.